Not available
Quote | Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Last: | $39.93 |
---|---|
Change Percent: | -0.7% |
Open: | $40.13 |
Close: | $40.21 |
High: | $40.578 |
Low: | $39.645 |
Volume: | 47,579 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
2024-06-30 09:25:12 ET Summary Mereo BioPharma Group plc has seen a rebound in its stock over the past year, with positive analyst commentary in the second quarter. The company is focused on developing therapeutics for oncology and rare diseases, with a lead candidate for Osteogen...
2024-06-14 05:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Subject | By | Source | When |
---|---|---|---|
News; $RARE Ultragenyx Pharmaceutical Inc ($RARE) Q3 2020 | whytestocks | investorshub | 10/28/2020 11:15:29 AM |
Lets go !!! | Erz | investorshub | 06/02/2020 7:04:41 PM |
News: $RARE Ultragenyx Announces Sale of Future European | whytestocks | investorshub | 12/19/2019 2:00:42 AM |
News: $RARE Ultragenyx Expands Leadership Team and Promotes | whytestocks | investorshub | 06/17/2019 8:50:42 PM |
What does this Miss Primary end points mean | Scalp2Trade | investorshub | 10/26/2018 1:07:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
2024-06-14 05:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that it has commenced an underwritten p...
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear sufficient for a biologics license application (BLA) submission NOVATO, Calif., June ...